Current principles of symptomatic treatment of lymphovenous insufficiency

This article provides a review of the current literature on principles symptomatic treatment lymphovenous insufficiency. Lymphovenous insufficiency is an urgent problem modern phlebology, prevalence this pathology reaches 50% among world population. Underlying pathogenesis venous hypertension, which caused by valve insufficiency, outflow obstruction, or combined causes. The use compression knitwear and therapy for important component at initial stages disease — pharmacotherapy based venoactive drugs. most promising to date are preparations micronized purified flavonide fraction (MPFF) group, consist diosmin flavonides. МОФФ drugs reduces hypertension increasing tone, reducing capacity, extensibility vessel wall. MPFF also improves lymph conversion contractility lymphatic capillaries has effect microcirculation vessels lower extremities, having resistance permeability capillaries. Thus, flavonides more pronounced etiology disease, thereby clinical leading effective result in And as presented review, containing flavonoid excellent candidate be further studied therapeutic agents because mechanism action directly connected with its pathophysiology high efficacy.